Arecaidine but-2-ynyl ester tosylate
Discontinued ProductUnfortunately Arecaidine but-2-ynyl ester tosylate (Cat. No. 0382) has been withdrawn from sale for commercial reasons.
Potent muscarinic agonist, 4.6-fold selective for M2 receptors in the atrium versus those in the ileum.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 365.44. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.74 mL||13.68 mL||27.36 mL|
|5 mM||0.55 mL||2.74 mL||5.47 mL|
|10 mM||0.27 mL||1.37 mL||2.74 mL|
|50 mM||0.05 mL||0.27 mL||0.55 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Barlow and Weston-Smith (1985) The relative potencies of some agonists at M2 muscarinic receptors in guinea pig ileum, atria and bronchi. Br.J.Pharmacol. 85 437 PMID: 3896364
Moser et al (1989) Structure-activity relationships of new analogues of arecaidine propargyl ester at muscarinic M1 and M2 receptor subtypes. Br.J.Pharmacol. 96 319 PMID: 2924082
View Related Products by Product Action
Keywords: Arecaidine but-2-ynyl ester tosylate, supplier, Muscarinic, agonists, Receptors, Acetylcholine, Ach, butynyl, M2, Receptors, Tocris Bioscience
Citations for Arecaidine but-2-ynyl ester tosylate
Citations are publications that use Tocris products.
Currently there are no citations for Arecaidine but-2-ynyl ester tosylate.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.